Status:
COMPLETED
Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients
Lead Sponsor:
University of Lahore
Conditions:
Corona Virus Infection
Eligibility:
All Genders
Phase:
NA
Brief Summary
In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization
Eligibility Criteria
Inclusion
- Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group
Exclusion
- allergic to nitroglycerin sudden drop in blood pressure not given consent
Key Trial Info
Start Date :
November 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2022
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT04686760
Start Date
November 15 2020
End Date
March 15 2022
Last Update
May 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bahria Town International Hospital
Lahore, Punjab Province, Pakistan, 54000